A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R

NCT07513649 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-07

No results posted yet for this study

Summary

A study to evaluate the bioequivalence of DA-5230 compared to DA-5230-R

Conditions

  • Healthy Adult Participants

Interventions

DRUG

DA-5230

Test drug

DRUG

DA-5230-R

Reference drug

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2026-05-31
Completion
2026-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07513649 on ClinicalTrials.gov